JAZZJazz PharmaceuticalsRunning, no new patients
A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers
Gastric Neoplasms · Gastroesophageal Adenocarcinoma · Esophageal Adenocarcinoma
2Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +1.5
3 insiders sold shares within a month
Since May 28, 2026 · was worth 10, fading over time
Worry score2
Score over time
- Stage
- Phase 3
- Patients
- 920 (final count)
- Started
- Dec 2, 2021
- Main results expected
- Jul 15, 2026
- Fully finished
- Sep 30, 2027
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Progression-free survival (PFS) by BICR
Measured over: Up to 2.5 years
Overall survival
Measured over: Up to 3.5 years
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 10, now 1.5, since 2026-05-28, fades (half-life)
Raw record changes
- none yet
Trial ID NCT05152147 · record last updated 2026-10-20 · checked 2026-11-09 15:47 UTC